Juan Carlos Amador-Molina

Juan Carlos Amador-Molina

Auto-generated profile, based on publicly available information

Juan Carlos Amador-Molina

The University of Texas MD Anderson Cancer Center 6 Department of Translational Molecular Pathology Houston, Texas

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2013 in Infection and Immunity
Verified
Journal Article
Open access
PDF file
AVAnita Verma
Anita Verma
BMBeth McNichol
Beth McNichol
RDRocío I. Domínguez-Castillo
Rocío I. Domínguez-Castillo
JAJuan C. Amador-Molina
Juan C. Amador-Molina
JAJuan L. Arciniega
Juan L. Arciniega
DBDrusilla L. Burns
Drusilla L. Burns
Long-term stability is a desired characteristic of vaccines, especially anthrax vaccines, which must be stockpiled for large-scale use in an emergency situation; however, spontaneous deamidation of purified vaccine antigens has the potential to adversely affect vaccine immunogenicity over time. In order to explore whether spontaneous deamidation of recombinant protective antigen (rPA)—the major component of new-generation anthrax vaccines—affects vaccine immunogenicity, we created a “genetically deamidated” form of rPA using site-directed mutagenesis to replace six deamidation-prone asparagine residues, at positions 408, 466, 537, 601, 713, and 719, with either aspartate, glutamine, or alanine residues. We found that the structure of the six-Asp mutant rPA was not significantly altered relative to that of the wild-type protein as assessed by circular dichroism (CD) spectroscopy and biological activity. In contrast, immunogenicity of aluminum-adjuvanted six-Asp mutant rPA, as measured by induction of toxin-neutralizing antibodies, was significantly lower than that of the corresponding wild-type rPA vaccine formulation. The six-Gln and six-Ala mutants also exhibited lower immunogenicity than the wild type. While the wild-type rPA vaccine formulation exhibited a high level of immunogenicity initially, its immunogenicity declined significantly upon storage at 25°C for 4 weeks. In contrast, the immunogenicity of the six-Asp mutant rPA vaccine formulation was low initially but did not change significantly upon storage. Taken together, results from this study suggest that spontaneous deamidation of asparagine residues predicted to occur during storage of rPA vaccines would adversely affect vaccine immunogenicity and therefore the storage life of vaccines.

1 July 2016 in Vaccine
Verified
Journal Article
Closed access
JAJuan C. Amador-Molina
Juan C. Amador-Molina
EVEsther D. Valerdi-Madrigal
Esther D. Valerdi-Madrigal
RDRocío I. Domínguez-Castillo
Rocío I. Domínguez-Castillo
LSLev A. Sirota
Lev A. Sirota
JAJuan L. Arciniega
Juan L. Arciniega

1 March 2013 in Biologicals
Verified
Journal Article
Closed access
RDRocío I. Domínguez-Castillo
Rocío I. Domínguez-Castillo
AVAnita Verma
Anita Verma
JAJuan C. Amador-Molina
Juan C. Amador-Molina
LSLev Sirota
Lev Sirota
JAJuan L. Arciniega
Juan L. Arciniega

25 May 2011 in Clinical and Vaccine Immunology
Verified
Journal Article
Open access
PDF file
JSJ. Serafín-López
J. Serafín-López
MTM. Talavera-Paulin
M. Talavera-Paulin
JAJ. C. Amador-Molina
J. C. Amador-Molina
MAM. Alvarado-Riverón
M. Alvarado-Riverón
MVM. M. Vilchis-Landeros
M. M. Vilchis-Landeros
IEI. Estrada-García
I. Estrada-García
Leprosy is an infectious disease caused byMycobacterium leprae, which is a noncultivable bacterium. One of the principal goals of leprosy research is to develop serological tests that will allow identification and early treatment of leprosy patients.M. habanais a cultivable nonpathogenic mycobacterium and candidate vaccine for leprosy, and several antigens that cross-react betweenM. lepraeandM. habanahave been discovered. The aim of the present study was to extend the identification of cross-reactive antigens by identifyingM. habanaproteins that reacted by immunoblotting with antibodies in serum samples from leprosy patients but not with antibodies in sera from tuberculosis (TB) patients or healthy donors (HDs). A 28-kDa antigen that specifically reacted with sera from leprosy patients was identified. To further characterize this antigen, protein spots were aligned in two-dimensional polyacrylamide gels and Western blots. Spots cut out from the gels were then analyzed by mass spectrometry. Two proteins were identified: enoyl-coenzyme A hydratase (lipid metabolism; ML2498) and antigen 85B (Ag85B; mycolyltransferase; ML2028). These proteins represent promising candidates for the design of a reliable tool for the serodiagnosis of lepromatous leprosy, which is the most frequent form in Mexico.

12 June 2026 in Clinical Cancer Research
Verified
Journal Article
Open access
HCHelen D. Clark
Helen D. Clark
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
JSJake Schladenhauffen
Jake Schladenhauffen
JDJonathon Debonis
Jonathon Debonis
JAJuan Carlos Amador-Molina
Juan Carlos Amador-Molina
SWShannon N. Westin
Shannon N. Westin
Purpose: Platinum-resistant high-grade serous ovarian carcinomas (HGSOC) are associated with poor therapeutic outcomes. Although HGSOC frequently metastasizes to the intraperitoneal (IP) cavity, the success of IP cytokine therapies, such as IL2, has been hampered by local toxicity and administration difficulties. AVB-001 is a novel IL2 delivery system consisting of encapsulated, allogeneic cells engineered for constitutive human IL2 (hIL2) expression. Patients and Methods: This is a phase I dose-escalation trial of AVB-001 for the treatment of HGSOC (NCT05538624). A single dose of AVB-001 was administered by IP laparoscopy, enabling hIL2 doses from 0.6 to 3.6 μg hIL2/kg/day. Safety was evaluated using NCI Common Terminology Criteria for Adverse Events v5.0. Efficacy was assessed via Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 and immunotherapy RECIST criteria. Results: The trial enrolled 14 patients across four dose levels. Three (21.4%) patients experienced grade 3 treatment-related adverse events (TRAE); no grade 4 to 5 TRAEs were reported. There was one dose-limiting toxicity. There was one unconfirmed partial response but no confirmed responses (overall response rate 0%). Stable disease was observed in seven patients, with a median duration of 2.57 months (range, 2.03–4.23). The clinical benefit rate was 14.3% (n = 2). Pharmacokinetics demonstrated dose-dependent increases in serum IL2, peaking at 1 day after implantation. Immunologic analyses revealed sustained CD8+ and CD4+ T-cell proliferation without corresponding proliferation in regulatory T cells. Dose-dependent CTLA-4 receptor upregulation was observed on CD8+ and CD4+ T cells, whereas PD-1 and TIM-3 remained unchanged. Conclusions: In patients with HGSOC, AVB-001 is safe and effectively activates cytotoxic T cells, supporting further investigation of this locoregional immunotherapy.

3 August 2026
Verified
Other
Open access
HCHelen D. Clark
Helen D. Clark
SASamira Aghlara-Fotovat
Samira Aghlara-Fotovat
JSJake Schladenhauffen
Jake Schladenhauffen
JDJonathon Debonis
Jonathon Debonis
JAJuan Carlos Amador-Molina
Juan Carlos Amador-Molina
SWShannon N. Westin
Shannon N. Westin
Collated supplementary tables 1-10 and supplementary text